Skip to main content
Download PDF

Diabetic dyslipidemia and its predictors among people with diabetes in Ethiopia: systematic review and meta-analysis

Systematic Reviews volume 13, Article number: 190 (2024) Cite this article

Abstract

Background

Dyslipidemia is an imbalance of lipid profiles. It increases the chance of clogged arteries and may cause heart attacks, strokes, and other circulatory disorders. Dyslipidemia affects the general population, but its severity is higher in diabetic populations. As a result, the chance of dyslipidemia-associated morbidity and mortality is highest in diabetic patients. In Ethiopia, around 2 to 6.5% of the population live with diabetes, but their lipid profiles are inconsistent across the studies. Therefore, this study aimed to estimate the pooled prevalence of diabetic dyslipidemia and its predictors among people with diabetes in Ethiopia.

Method

A systematic review and meta-analysis was conducted. The searches were carried out in MEDLINE via PubMed and OVID, EBSCO, Embase, and other supplementary gateways such as Google and Google Scholar, for articles published up to June 2023. The articles were searched and screened by title (ti), abstract (ab), and full text (ft). The quality of the eligible studies was assessed by the Newcastle–Ottawa scale. The heterogeneity was detected by the Cochrane Q statistic test and the I-squared (I2) test. Then subgroup analysis and meta-regression analysis were used to identify the source of the variations. A random or fixed-effect meta-analysis model was used to estimate the overall pooled prevalence and average effects. The publication bias was assessed by the funnel plot asymmetry test and/or Begg and Mazumdar’s test for rank correlation (p-value < 0.05). The protocol has been registered in an international database, the prospective register of systematic reviews (PROSPERO), with reference number CRD42023441572.

Result

A total of 14 articles with 3662 participants were included in this review. The pooled prevalence of diabetic dyslipidemia in Ethiopia was found to be 65.7% (95% confidence interval (CI): 57.5, 73.9), I2 = 97%, and p-value < 0.001. The overall prevalence of triglycerides (TG) and high-density lipoprotein cholesterol (HDL-c) were found to be 51.8% (95% CI: 45.1, 58.6) and 44.2% (95% CI: 32.8, 55.7), respectively, among lipid profiles. In meta-regression analysis, the sample size (p value = 0.01) is the covariate for the variation of the included studies. Being female (adjusted odds ratio (AOR): 3.9, 95% CI: 1.5, 10.1), physical inactivity (AOR: 2.6, 95% CI: 1.5, 4.3), and uncontrolled blood glucose (AOR: 4.2, 95% CI: 1.9, 9.4) were found to be the determinants of dyslipidemia among diabetic patients.

Conclusion

This review revealed that the prevalence of diabetic dyslipidemia is high among people with diabetes in Ethiopia. Being female, having physical inactivity, and having uncontrolled blood glucose were found to be predictors of dyslipidemia among people with diabetes. Therefore, regular screening of lipid profiles and the provision of lipid-lowering agents should be strengthened to reduce life-threatening cardiovascular complications. Furthermore, interventions based on lifestyle modifications, such as regular physical activity and adequate blood glucose control, need to be encouraged.

Peer Review reports

Background

Diabetes mellitus (DM) is the leading public health challenge worldwide [1]. Globally, around 537 million people have DM. Over three in four adults with diabetes live in low- and middle-income countries (LMICs). It is one of the top ten leading causes of death globally [2] and is responsible for the direct cause of 1.5 million deaths [3]. Similarly, diabetes is one of the top nine causes of death in LMICs [4]. The prevalence of DM in Ethiopia has been reported to range from 2 to 6.5% [5].

Dyslipidemia is a lipoprotein metabolism disorder, including lipoprotein overproduction or deficiency [6, 7]. It is characterized by elevated fasting and postprandial triglycerides (TG), low in high-density lipoprotein-cholesterol (HDL-C), elevated low-density lipoprotein cholesterol (LDL-C), and the predominance of low-density lipoprotein (LDL) particles [8]. The causes of dyslipidemia may be primary (genetic) or secondary, which are caused by lifestyle or other factors. It affects the general population, but its prevalence is highest in diabetic patients [9]. The mechanism for the development of dyslipidemia is not clearly understood in diabetics, but it is associated with insulin resistance, elevated blood glucose levels, excessive production of rich lipoproteins from the liver [10], and problems with lipid enzymes. About 61% of diabetic patients have at least one or more elevated liver enzymes [11]. A high-fat and high-calorie diet can cause dyslipidemia and lead to endothelial dysfunction [12]. Dyslipidemia clogs arteries, which contributes to the development of atherosclerosis and cardiovascular disease. These result in coronary artery diseases, peripheral vascular diseases, heart attacks, stroke, hypertension, heart failure, renal disease, and others [13, 14]. In order to overcome the negative effects of dyslipidemia, intervention strategies including regular follow-up care, health education on lifestyle modifications, and providing lipid-lowering agents have been implemented [15,16,17]. In Ethiopia, studies have reported on the prevalence of dyslipidemia among people with diabetes, but their findings are inconsistent across studies. Therefore, this review aimed to estimate the pooled prevalence of dyslipidemia and identify its predictors among people with diabetes in Ethiopia.

Methods

Study protocol registration and reporting

The protocol for this review has been registered on PROSPERO with reference number CRD42023441572. The report of this review followed the systematic review and meta-analysis (PRISMA) guideline checklist [18] (Additional File 1).

Searching strategies and selections

The searches were carried out in MEDLINE via PubMed and OVID, EBSCO, Embase, and other supplementary gateways such as Google and Google Scholar. The Boolean operators of OR and AND were used to combine the search terms. Articles were searched by title (ti), abstract (ab), and/or full text (ft). The search string is stated as dyslipidemia OR “abnormal lipid profile*” OR hyperlipidemia AND “diabetes mellitus” OR DM OR “Type 2 diabetes mellitus” OR T2DM OR “Type 1 diabetes mellitus” OR T1DM AND Ethiopia. All search results were exported to Rayyan software to screen and de-duplicate the articles. Two collaborators (Z. B. T. and G. J.) were invited and screened articles independently based on the eligibility criteria. Then, the disagreements were resolved through discussion. EndNote reference management software version 7 was used to cite the references. The searches included articles published up to June 2023. The search was carried out from June 1 to 30, 2023.

Inclusion and exclusion criteria

Studies were eligible for inclusion in the review if they reported on the following: (1) adult (age ≥ 18 years), diabetic (type 1 and/or type 2 diabetic), and population groups (2) were observational in design (i.e., cross-sectional, cohort, and case control); (3) reported the prevalence, proportion, or incidence of dyslipidemia; (4) were conducted in Ethiopia; (5) were published or unpublished; and (6) took place in primary, general, and/or tertiary hospitals and were included in the study. On the contrary, articles with abstracts only and conference papers were excluded. Moreover, articles with narrative reviews, systematic reviews, and meta-analyses were also excluded.

Outcome measurement

Dyslipidemia was defined as TC ≥ 200 mg/dl, or TG ≥ 150 mg/dl, or LDL-C ≥ 130 mg/dl, or HDL-C < 40 mg/dl (for men) and HDL-C < 50 (for women) [12]. Diabetes was defined as fasting blood glucose ≥ 126 mg/dl, HbA1c ≥ 7%, or patients on antidiabetic medication treatments [19].

Quality assessment

The quality of the included studies were assessed by a modified Newcastle–Ottawa quality assessment scale (NOS) adapted from cross-sectional [20] and case–control studies [21]. The tool used a “star scoring system” based on three parameters. These were study selection, comparability of the group, and ascertainment of the exposure and outcome status. For cross-sectional studies, a maximum of 9 stars could be allocated, and for case–control studies, a maximum of 10 stars [22]. For the current review, a study of any design that received a rating of 7 or more stars was considered to be of high methodological quality [21]. Two reviewers independently reviewed the quality of the included studies, and any discrepancies between reviewers were resolved by discussion.

Data extraction

The data were extracted using the Microsoft Word data extraction format. The format was developed by involving all the reviewers. The data extraction format was piloted among two eligible studies before extracting the data. Then, further modifications were made accordingly. The extracted data include author(s), year of publications, region, study design, population, sample size, data collection procedure, prevalence, and funding source (Additional File 2). Furthermore, to assess the predictors of diabetic dyslipidemia, the effect estimate so-called odds ratio was used. This was taken from the reports of the previous studies or calculated from their cross-tabs [23]. Two reviews (Z. B. T. and G. J.) independently retrieved the data from the studies. The disagreements between the reviewers were resolved by the discussion or involvement of the third reviewer.

Data analysis

The retrieved data were exported into Stata version 14 for analysis. A random and/or fixed-effect meta-analysis model was used to estimate the pooled prevalence and average effects on dyslipidemia based on the presence of heterogeneity. The presence of heterogeneity was detected by a nonparametric statistical test called the Cochrane Q test, whereas the proportion of heterogeneity was estimated using I squared (I2) statistics. The I2 test statistics of 0.0 to 30%, 30 to 60%, and 60 to 100% were considered minimal, moderate, and substantial heterogeneity [24, 25], respectively. To see the level of variation across the studies, subgroup analyses by region of the study were computed. Furthermore, a random-effect meta-regression analysis was carried out to identify the covariates of the variations. As a result, publication years and sample size were used for the regression analysis. The publication bias was detected by visual inspection of the funnel plot and/or Begg’s or Egger’s linear regression test (p-value < 0.05).

Results

Study selection and characteristics

The search retrieved 1644 original research articles. From this, 356, 997, and 105 articles were removed due to duplication, background articles, and population differences, respectively. Then, after, 186 articles were retrieved, and 168 articles were removed, of which 10 were removed because not full text (abstracts only) and 158 were not related to the topic of interest. About 18 full-text articles were accessed for eligibility, of which four articles were excluded because of poor quality after NOS assessment, reporting without the outcome of interest, and outcome measurement (Fig. 1). Finally, 14 articles with 3662 diabetic patients were included and retrieved for this review. From studies, five were in Ahmara [26,27,28,29,30], four in SNNP [31,32,33,34], three in Oromia [35,36,37], one in Tigry [38], and one in Addis Ababa [39]. Thirteen were cross-sectional in design, and the remaining was case control. The publication years of the included studies were between 2017 and 2022. The data collection methods of the majority of the included studies were interviewer-administered surveys. The overall quality appraisal of the included studies was ≥ 7 (Table 1).

Fig. 1
figure 1

PRISMA flow diagram for the flow of information through the phases of the review

Full size image
Table 1 Characteristics of the included studies
Full size table

The prevalence of diabetic dyslipidemia ranges from 37.5% [37] to 91.1% [34]. The predominant lipid abnormality was elevated triglycerides. Regarding factors, two articles for sex [35, 37], two articles for physical activity [29, 36], and two articles for blood glucose control status [29, 36] were used (Table 2).

Table 2 Diabetes and lipid profiles related characteristics among people with diabetes in Ethiopia
Full size table

Prevalence of diabetic dyslipidemia

The pooled prevalence of dyslipidemia among people with diabetes in Ethiopia was found to be 65.68% (95% CI: 57.5, 73.9), I2 = 97%, p-value < 0.001) using a random-effect meta-analysis model (Fig. 2). Regarding the lipid profiles, the pooled prevalence of TG and HDL-C was 51.8% (95% CI: 45.1, 58.6) and 44.2% (95% CI: 32.8, 55.7), respectively (Table 3).

Fig. 2
figure 2

Forest plot shows the pooled prevalence of dyslipidemia among diabetic patients in Ethiopia

Full size image
Table 3 Lipid profiles among diabetic patients
Full size table

Heterogeneity test

As shown in the forest plot (Fig. 2), the proportion of variation was 97% and the Cochrane Q statistic p-value < 0.001, indicating there is considerable variation across the studies. Therefore, further subgroup analysis and random-effect meta-regression analysis were computed.

Subgroup analysis

The subgroup analysis was computed by the region of the studies. From the included studies, the pooled prevalence of dyslipidemia among people with diabetes was 77.5% (95% CI: 65.3, 89.6), I2 = 96.2%, p < 0.001 in SNNP, 64.4% (95% CI: 59.2, 69.6), I2 = 70%, p = 0.01 in Amhara, and 63.8% (95% CI: 46.0, 81.6), I2 = 95.6%, p = 0.001 in the Oromia region using a random-effect meta-analysis model (Fig. 3).

Fig. 3
figure 3

The subgroup analysis of the included studies

Full size image

Meta-regression

To identify the factors attributed to the variations across the included studies, sample size and publication years were used. In this random effect meta-regression analysis, the sample size is found to be the covariate, possibly the source of variation or heterogeneity across the included studies (p-value = 0.01) (Table 4).

Table 4 Meta-regression analysis of studies on diabetic dyslipidemia
Full size table

Publication bias

The publication bias was detected by visual inspection of the funnel plot, indicating a symmetrical distribution of articles, and Egger’s linear regression test p-value was 0.37, meaning that there is no publication bias (Fig. 4).

Fig. 4
figure 4

Funnel plot shows the distribution of included articles

Full size image

Determinants of diabetic dyslipidemia

Female

Being female is found to be the determinant factor of dyslipidemia among people with diabetes. Female diabetic patients are 3.9 times more likely to develop dyslipidemia compared with their male counterparts (AOR: 3.9, 95% CI: 1.5, 10.1; I2 = 35.3%, p = 0.21) using a random effect model (Fig. 5). As shown in the forest plot, the variation between studies is 35.3%, indicating there is minimal heterogeneity. Regarding publication bias, Begg and Mazumdar’s test for rank correlation gave a p-value of 0.32, indicating no evidence of publication bias.

Fig. 5
figure 5

The effect of sex on dyslipidemia among diabetic patients

Full size image

Physical inactivity

Physical inactivity is found to be the determinant factor of dyslipidemia among people with diabetes. Diabetic patients who do not do physical activity were 2.6 times more likely to develop dyslipidemia compared to those people with diabetes who do physical activity (AOR: 2.6, 95% CI: 1.5, 4.3; I2 = 0.0%, p = 0.82). The I2 test statistic is 0.0%, and the p-value is 0.82, which indicates there is minimal heterogeneity across the included studies (Fig. 6). On further testing, Begg and Mazumdar’s test rank correlation gave a p-value of 1.00, indicating there is no publication bias.

Fig. 6
figure 6

The effect of physical inactivity on dyslipidemia among diabetic patients

Full size image

Uncontrolled blood glucose

In this systematic review and meta-analysis, diabetic patients who have uncontrolled blood glucose are at risk for dyslipidemia. People with diabetes who have uncontrolled blood glucose are 4.2 times more likely to develop dyslipidemia compared to those with controlled diabetes (AOR: 4.2, 95% CI: 1.9, 9.4; I2 = 19.4%, p = 0.27). The I2 and Cochrane Q statistics p-values are 19.4% and 0.27, respectively (Fig. 7). These indicate that there is minimal variation across the studies. Begg and Mazumdar’s test for rank correlation gave a p-value of 0.32, indicating there is no evidence of publication bias.

Fig. 7
figure 7

The effect of uncontrolled blood sugar on dyslipidemia among diabetic patients

Full size image

In addition to the above factors, the effects of some sociodemographic, personal-related, and clinical factors on dyslipidemia among people with diabetes in Ethiopia are summarized (Additional File 3).

Discussion

In this systematic review and meta-analysis, the pooled prevalence of diabetic dyslipidemia was 65.7% (95% CI: 57.5, 73.9). The study includes both type 1 and type 2 diabetic patients in Ethiopia. Based on the regions of Ethiopia, the prevalence of diabetic dyslipidemia was 77.5% (95% CI: 65.3, 89.6) in SNNP, 64.4% (95% CI: 59.2, 69.6) in Amhara, and 63.8% (95% CI: 46.0, 81.6) in the Oromia region. The findings of this study are higher than those of the studies conducted in 10 African countries: 52.8% [40] and 25.5% [41]. The possible discrepancy is variation in the study population. In the African studies, the participants were both diabetic and nondiabetic populations and the general population, but the current study focused on diabetic patients.

Based on the lipid profiles, the pooled prevalence of TC, TG, LDL-c, and HDL-c were found to be 34.7% (95% CI: 23.3, 46.0), 51.8% (95% CI: 45.1, 58.6), 34.4% (95% CI: 22.3, 46.6), and 44.2% (95% CI: 32.8, 55.7), respectively. This finding is in line with the study in Orlando, Florida, TC 30.08% [42]. In this study, the findings of TG and LDL-c are higher than those of the study conducted in Orlando, Florida: TG 24.82% and LDL-c 18.62%. The variation may be associated with lifestyle modification issues such as physical activity and healthy eating. In addition, socio-economic status plays a vital role in this discrepancy.

In the meta-regression analysis, sample size is the source of the variation for the included studies. The finding of this study is supported by the study conducted in the USA, which dictates that heterogeneity between small studies is greater than between larger studies [43]. This is due to studies with a large sample size, which gives a narrow confidence interval and good precision [44].

In this systematic review and meta-analysis, female diabetic patients are at risk for developing dyslipidemia. The finding is supported by a large survey study in Spain [45] and China [46]. In their reproductive years, the females have a low LDL level, but it rises after menopause. This is associated with female sex hormones such as estrogens, which have a lowering effect specifically on LDL [47, 48]. After the menopause phase, the estrogen level decreased, which in turn increased the LHD levels. Estrogen in women causes a high level of good HDL cholesterol and maintains the bad LDL cholesterol to a lower normal limit during the monthly menstruation cycle [49]. But at a later age, these conditions reverse and lead to a progressive rise in LDL cholesterol levels [50].

People with diabetes who are physically inactive are at risk for dyslipidemia. This is due to the fact that physical inactivity increases visceral fat accumulation, stimulates chronic low-grade systemic inflammation, and leads to insulin resistance and dyslipidemia [51]. Sedentary lifestyles increase the deposit of bad cholesterol. This contributes to endothelial dysfunction and atherosclerosis [52], and in later life, this results in life-threatening cardiovascular complications [14]. Furthermore, the findings of this study showed that uncontrolled blood glucose is the determinant of dyslipidemia among people with diabetes. Glucose and lipid metabolism are linked to each other in many ways, which leads to diabetic dyslipidemia or increased lipid profiles [53]. Evidence has been reported that dyslipidemia is associated with insulin resistance and increased lipid metabolism [54, 55].

This review has the following important limitations: (1) The study included both diabetic patients, such as type 1 and/or type 2, and as a result, it does not clearly show which population type is more affected. Therefore, further study is needed on type 1 or type 2 diabetic patients separately. In the positive aspects, the authors used major databases to search related articles and screened them independently using Rayyan software.

Implications of the study

The main finding is the considerable, unexplained variation in prevalence. The study highlights the prevalence of dyslipidemia among people with diabetes. The findings of the study provide input to healthcare workers on how to carry out regular lipid profile screening to prevent, detect, and treat lipid profile abnormalities to minimize possible complications. Furthermore, it helps decision-makers and policymakers plan preventive measures before the occurrence of life-threatening cardiovascular complications.

Conclusion

This review revealed that the prevalence of diabetic dyslipidemia is high among people with diabetes in Ethiopia. Being female, having physical inactivity, and having uncontrolled blood glucose were the predictors of dyslipidemia. In Ethiopia, lipid-lowering agents and antidiabetic treatments have been routinely provided for people with diabetes with comorbid dyslipidemia. Therefore, regular screening of lipid profiles and treatment of hyperglycemia should be strengthened. Furthermore, lifestyle modification interventions such as a healthy diet, regular physical exercise, and adequate blood glucose control need to be encouraged to reduce life-threatening cardiovascular complications. Healthcare providers should also give special attention to women living with diabetes.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Abbreviations

CVD:

Cardiovascular diseases

DM:

Diabetes mellitus

HDL-C:

High-density lipoprotein cholesterol

LDL-C:

Low-density lipoprotein cholesterol

PRISMA:

Preferred Reporting Items of Systematic reviews and Meta-Analysis

PROSPERO:

Prospective register of systematic reviews

SNNPR:

Southern Nation, Nationalities, and Peoples’ Region

T2DM:

Type 2 diabetes mellitus

References

  1. Arredondo A, Azar A, Recamán AL. Diabetes, a global public health challenge with a high epidemiological and economic burden on health systems in Latin America. Glob Public Health. 2018;13(7):780–7.

    Article  PubMed  Google Scholar 

  2. Nam H. Cho. Diabetes: a global health challenge. 2018. https://www.openaccessgovernment.org/diabetes-a-global-health-challenge/46992. April 30/2024

    Google Scholar 

  3. Metrics I. for H. & Evaluation. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD 2016) Results.(2017). 5. Institute for Health Metrics and Evaluation Seattle. 2019.

  4. The top 10 causes of death. 9 December 2020, https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death, April 30/2024

  5. Bishu KG, Jenkins C, Yebyo HG, Atsbha M, Wubayehu T, Gebregziabher M. Diabetes in Ethiopia: a systematic review of prevalence, risk factors, complications, and cost. Obesity Medicine. 2019;15:100132.

    Article  Google Scholar 

  6. Kopin L, Lowenstein CJ. Dyslipidemia. Ann Intern Med. 2017;167(11):ITC81–96. https://doi.org/10.7326/AITC201712050.

    Article  PubMed  Google Scholar 

  7. Mancini GJ, Hegele RA, Leiter LA, Committee DCCPGE. Dyslipidemia Canadian journal of diabetes. 2018;42:S178–85.

    Article  PubMed  Google Scholar 

  8. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63(12):1469–79.

    Article  CAS  PubMed  Google Scholar 

  9. Pathak R, Pathak A. Study of life style habits on risk of type 2 diabetes. Int J Appl Basic Med Res. 2012;2(2):92.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86(3):965–71.

    Article  CAS  PubMed  Google Scholar 

  11. Kathak RR, Sumon AH, Molla NH, Hasan M, Miah R, Tuba HR, et al. The association between elevated lipid profile and liver enzymes: a study on Bangladeshi adults. Sci Rep. 2022;12(1):1711.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020;19:1–11.

    Article  Google Scholar 

  13. Narindrarangkura P, Bosl W, Rangsin R, Hatthachote P. Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand. Lipids Health Dis. 2019;18:1–8.

    Article  Google Scholar 

  14. Chen S-c, Tseng C-H. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud. 2013;10(2–3):88.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Jialal I, Singh G. Management of diabetic dyslipidemia: an update. World J Diabetes. 2019;10(5):280.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006;8(4):191–203.

    PubMed  Google Scholar 

  17. Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN. Screening and treating adults for lipid disorders. Am J Prev Med. 2001;20(3):77–89.

    Article  CAS  PubMed  Google Scholar 

  18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.

    Article  PubMed  Google Scholar 

  19. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. 2006.

  20. Moskalewicz A, Oremus M. No clear choice between Newcastle-Ottawa scale and appraisal tool for cross-sectional studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer. J Clin Epidemiol. 2020;120:94–103.

    Article  PubMed  Google Scholar 

  21. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011;2(1):1–12.

    Google Scholar 

  22. Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World Journal of Meta-Analysis. 2017;5(4):80–4.

    Article  Google Scholar 

  23. Cleophas TJ, Zwinderman AH, Cleophas TJ, Zwinderman AH. Odds ratios, a short-cut for analyzing cross-tabs. Clinical Data Analysis on a Pocket Calculator: Understanding the Scientific Methods of Statistical Reasoning and Hypothesis Testing. 2nd ed. 2016. p. 249–52.

  24. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I 2 in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8:1–9.

    Article  Google Scholar 

  25. Fletcher J. What is heterogeneity and is it important? BMJ. 2007;334(7584):94–6.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kebede WM, Gizachew KD, Mulu GB. Prevalence and risk factors of dyslipidemia among type 2 diabetes patients at a referral hospital, north eastern Ethiopia. Ethiopian Journal of Health Sciences. 2021;31(6):1267–76.

    PubMed  PubMed Central  Google Scholar 

  27. Biadgo B, Melak T, Ambachew S, Baynes HW, Limenih MA, Jaleta KN, et al. The prevalence of metabolic syndrome and its components among type 2 diabetes mellitus patients at a tertiary hospital, northwest Ethiopia. Ethiopian journal of health sciences. 2018;28(5):645–54.

    PubMed  PubMed Central  Google Scholar 

  28. Wuhib M, Tegegne B, Mekonnen L, Mengesha Z, Girma M, Solomon M, et al. Correlation of dyslipidemia and athrogenic index of plasma with anthropometric measurements and clinical variables among diabetic patients in Dessie Comprehensive Specialized Hospital, Ethiopia, 2021. Annals of Clinical Gastroenterology and Hepatology. 2022;6(1):025–33.

    Article  Google Scholar 

  29. Fikremariam T, Reddy PCJ Prasad. Evaluation of dyslipidemia, nutritional status and other associated factors among diabetic mellitus patients at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia, 2018. DSpace Repository, DSpace Institution's institutional repository. 2020.

  30. Birarra MK, Gelayee DA. Metabolic syndrome among type 2 diabetic patients in Ethiopia: a cross-sectional study. BMC Cardiovasc Disord. 2018;18(1):1–12.

    Article  Google Scholar 

  31. Bekele S, Yohannes T, Mohammed AE. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region. Diabetes, metabolic syndrome and obesity: targets and therapy. 2017;10:265–71.

    Article  CAS  PubMed  Google Scholar 

  32. Woyesa SB, Hirigo AT, Wube TB. Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus patients at Hawassa University Comprehensive Specialized Hospital. South West Ethiopia BMC endocrine disorders. 2017;17:1–8.

    Google Scholar 

  33. Abebe G, Fikadu T, Hailu T, Temesgen R. Determinants of metabolic syndrome among type two diabetic patients following diabetic clinic of Arba Minch General hospital, southern Ethiopia-a case-control study. 2022.

  34. Wube TB, Begashaw TA, Hirigo AT. Prevalence of dyslipidemia and its correlation with anthropometric and blood pressure variables among type-2 diabetic patients. Journal of Diabetes and Endocrinology. 2020;11(1):10–7.

    Article  Google Scholar 

  35. Abdissa D, Hirpa D. Dyslipidemia and its associated factors among adult diabetes outpatients in West Shewa zone public hospitals, Ethiopia. BMC Cardiovasc Disord. 2022;22(1):39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Haile K, Timerga A. Dyslipidemia and its associated risk factors among adult type-2 diabetic patients at Jimma University Medical Center, Jimma, southwest Ethiopia. Diabetes, Metabolic Syndrome and Obesity. 2020;13:4589–97.

    Article  CAS  PubMed Central  Google Scholar 

  37. Woyesa S, Mamo A, Mekonnen Z, Abebe G, Gudina EK, Milkesa T. Lipid and lipoprotein profile in HIV-infected and non-infected diabetic patients: a comparative cross-sectional study design, southwest Ethiopia. HIV/AIDS-Research and Palliative Care. 2021;13:1119–26.

    Article  CAS  PubMed  Google Scholar 

  38. Gebremeskel GG, Berhe KK, Belay DS, Kidanu BH, Negash AI, Gebreslasse KT, et al. Magnitude of metabolic syndrome and its associated factors among patients with type 2 diabetes mellitus in Ayder Comprehensive Specialized Hospital, Tigray, Ethiopia: a cross sectional study. BMC Res Notes. 2019;12:1–7.

    Article  Google Scholar 

  39. Birlie M. Assessment of metabolic syndrome in relation to sex among type ΙΙ diabetes mellitus patients in Tikur Anbessa Specialized Hospital, Addis Ababa. Ethiopia: Addis Ababa university institutional repository; 2019.

    Google Scholar 

  40. Obsa MS, Ataro G, Awoke N, Jemal B, Tilahun T, Ayalew N, et al. Determinants of dyslipidemia in Africa: a systematic review and meta-analysis. Frontiers in cardiovascular medicine. 2022;8:778891.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Noubiap JJ, Bigna JJ, Nansseu JR, Nyaga UF, Balti EV, Echouffo-Tcheugui JB, et al. Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis. Lancet Glob Health. 2018;6(9):e998–1007.

    Article  PubMed  Google Scholar 

  42. Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: a systematic review and meta-analysis. Ophthalmology. 2015;122(9):1820–7.

    Article  PubMed  Google Scholar 

  43. IntHout J, Ioannidis JP, Borm GF, Goeman JJ. Small studies are more heterogeneous than large ones: a meta-meta-analysis. J Clin Epidemiol. 2015;68(8):860–9.

    Article  PubMed  Google Scholar 

  44. Liu XS. Sample size and the precision of the confidence interval in meta-analyses. Therapeutic Innovation & Regulatory Science. 2015;49(4):593–8.

    Article  Google Scholar 

  45. Soriano-Maldonado C, Lopez-Pineda A, Orozco-Beltran D, Quesada JA, Alfonso-Sanchez JL, Pallarés-Carratalá V, et al. Gender differences in the diagnosis of dyslipidemia: ESCARVAL-GENERO. Int J Environ Res Public Health. 2021;18(23):12419.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Wang M, Liu M, Li F, Guo C, Liu Z, Pan Y, et al. Gender heterogeneity in dyslipidemia prevalence, trends with age and associated factors in middle age rural Chinese. Lipids Health Dis. 2020;19(1):1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Thacker HL, Thacker H. Women’s Health: Your Body, Your Hormones. Your Choices: Cleveland Clinic Press; 2007.

    Google Scholar 

  48. El Khoudary SR, Chen X, Qi M, Derby CA, Brooks MM, Thurston RC, et al. The independent associations of anti-Müllerian hormone and estradiol levels over the menopause transition with lipids/lipoproteins: the study of women’s health across the nation. J Clin Lipidol. 2023;17(1):157–67.

    Article  PubMed  Google Scholar 

  49. Kennedy M. How does high cholesterol affect women and men differently? December 27, 2021.

  50. Currie H, Williams C. Menopause, cholesterol and cardiovascular disease. US Cardiology. 2008;5(1):12–4.

    Article  Google Scholar 

  51. Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Pathophysiology of physical inactivity-dependent insulin resistance: a theoretical mechanistic review emphasizing clinical evidence. J Diabetes Res. 2021;2021(1):7796727.

    PubMed  PubMed Central  Google Scholar 

  52. Laufs U, Wassmann S, Czech T, Münzel T, Eisenhauer M, Böhm M, et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(4):809–14.

    Article  CAS  PubMed  Google Scholar 

  53. Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J. 2015;39(5):353–62.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1999;84(1):28–32.

    Article  Google Scholar 

  55. Bonen A, Dohm GL, van Loon LJ. Lipid metabolism, exercise and insulin action. Essays Biochem. 2006;42:47–59.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the team members for their invaluable contribution from conception to final approval for submission to publication.

Funding

The authors did not receive any funding for this particular study.

Author information

Authors and Affiliations

  1. Department of Medical Nursing, School of Nursing, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

    Abere Woretaw Azagew, Hailemichael Kindie Abate, Chilot Kassa Mekonnen & Habtamu Sewunet Mekonnen

  2. Department of Comprehensive Nursing, School of Nursing, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

    Zewdu Baye Tezera

  3. Department of Physiotherapy, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

    Gashaw Jember

Authors
  1. Abere Woretaw Azagew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hailemichael Kindie Abate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chilot Kassa Mekonnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Habtamu Sewunet Mekonnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zewdu Baye Tezera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gashaw Jember
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AWA, HKA, CKM, HSM, ZBT, and GJ conceived and designed the study, and they should state that all authors have read and approved the final manuscript.

Corresponding author

Correspondence to Abere Woretaw Azagew.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: PRISMA checklist.

13643_2024_2593_MOESM2_ESM.docx

Additional file 2: Data availability statement. Table 1:  Study characteristics for the age of diabetic patients in Ethiopia.

Additional file 3: Summary of factors associated with dyslipidemia among diabetic patients in Ethiopia.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Azagew, A.W., Abate, H.K., Mekonnen, C.K. et al. Diabetic dyslipidemia and its predictors among people with diabetes in Ethiopia: systematic review and meta-analysis. Syst Rev 13, 190 (2024). https://doi.org/10.1186/s13643-024-02593-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13643-024-02593-2

Keywords

Systematic Reviews

ISSN: 2046-4053